Helex, a therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, has raised $3.5 million in a seed funding round led by pi Ventures, along with participation from Bluehill Capital, SOSV, and a global syndicate of investors.<\/p>\n
With this round, Helex has raised over $6 million in total funding to date. The proceeds will be used to accelerate its lead candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) while advancing its platform to establish a differentiated kidney therapeutics portfolio, Helex said in a press release.<\/p>\n
Co-founded in 2021 by Poulami Chaudhuri, Rohini Kalvakuntla, and Anirudh Nishtala, Helex is a therapeutics company developing a new class of targeted medicines for genetic kidney diseases using its proprietary LNP drug delivery and AI-based drug design platforms.<\/p>\n
Incubated at ASPIRE-BioNEST, University of Hyderabad, Helex aims to bring a paradigm shift in the treatment of chronic and rare kidney disorders by developing programmable, non-viral LNP therapeutics that deliver genetic payloads directly to kidney cells.<\/p>\n
According to Helex, its platform is powered by data-driven deep learning modeling using its own genomics data, bioinformatics, and high-throughput sequencing data from gene-edited target cells to create, verify, and deliver disease-specific gRNA.<\/p>\n
Helex says that its lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a progressive inherited disorder affecting more than 12 million people globally and nearly 5% of Chronic Kidney Disease (CKD) patients in India. It aims to change that with a single-dose, non-viral, gene-editing-based therapy that could halt or significantly slow disease progression.<\/p>\n
Disclaimer:<\/p>\n
Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever. You may find a list of our investors here<\/a>.<\/p>\n
![\"banner\"\/](\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/zG8sbRMt5HG04yMhLVd2.webp.webp\")
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Helex, a therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, has raised $3.5…\n","protected":false},"author":3,"featured_media":356671,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[64,607,173887,67,132,68],"class_list":{"0":"post-356670","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-entrepreneurship","8":"tag-business","9":"tag-entrepreneurship","10":"tag-helex","11":"tag-united-states","12":"tag-unitedstates","13":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115495333349954524","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/356670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=356670"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/356670\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/356671"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=356670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=356670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=356670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}